GAITHERSBURG, Md., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX ) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date and time: Wednesday, January 9, 3:00 p.m. – 3:25 p.m. P.T. Location: Colonial Room, Westin St. Francis Hotel, San Francisco Live webcast: www.novavax.com , “Investors”/“Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the website at www.novavax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX ) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn .
Contacts:
Investors Novavax, Inc. Erika Trahan ir@novavax.com 240-268-2000
Westwicke Partners John Woolford john.woolford@westwicke.com 443-213-0506
Media Sam Brown Andrea Cohen andreacohen@sambrown.com 917-209-7163